18F-FDG PET or PET/CT Parameters, Methods of Image Interpretation, and Reference Standard of Included Studies
| First author, year | 18F-FDG dose | Time between 18F-FDG administration and scanning (min) | Criteria for positive scan | Interpreters | Reference standard | Duration of clinical follow-up | Patients with recurrence (%) |
| Sharma, 2014 (17) | 370 MBq | 45–60 | Suggestive CT lesions with 18F-FDG uptake, suggestive CT lung lesion, 18F-FDG hotspot liver | 2 nuclear medicine physicians | Histology or clinical follow-up with imaging | Minimally 6 mo | NR |
| Sun, 2009 (18) | 60 MBq | 60 | Markedly to moderately increased uptake of 18F-FDG | 2 nuclear medicine physicians | Histology or clinical follow-up | Minimally 10 mo | 55.0 |
| Roedl, 2008 (19) | 555 MBq | 60 | Focal and eccentric uptake of 18F-FDG | Nuclear medicine physicians and radiologists. | Histology or clinical follow-up with imaging | NR | 57.4 |
| Guo, 2007 (20) | 370 MBq | 60 | Focal uptake of 18F-FDG | 3 nuclear medical physicians | Histology or clinical follow-up with imaging | Minimally 6 mo | 80.4 |
| Jadvar, 2006 (21) | 555 MBq | 60 | Focal uptake of 18F-FDG | NR | Histology or clinical follow-up with imaging | Up to 18 mo | 60.9 |
| Teyton, 2009 (22) | 355 MBq | 60 | Focal uptake of 18F-FDG | 2 nuclear medicine physicians | Histology or clinical follow-up with imaging | NR | 56.1 |
| Kato, 2004 (23) | 275–370 MBq | 40 | NR | 2 nuclear medicine physicians | Histology or clinical follow-up with imaging | Within 6 mo | 49.1 |
| Flamen, 2000 (24) | 6.5 MBq/kg, maximum 555 MBq | 60 | NR | 2 nuclear medicine physicians | Histology or clinical follow-up with imaging | Minimally 6 mo | 80.5 |
NR = not reported.